EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial

Loice Achieng Ombajo iD, Jeremy Penner iD, Joseph Nkuranga iD, Victor Omodi, Edwin Otieno, Florentius Ndinya, Simon Wahome, Anton Pozniak iD

Clinical Infectious Diseases · 30.04.2025 · 80 (4) · 889-892

DOI: 10.1093/cid/ciae514 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 26.11.2024. Verfasst von Loice Achieng Ombajo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya. Hauptthemen laut MEDLINE: Blood Pressure, Body Weight, Cardiovascular Diseases, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ViiV Healthcare, University of Nairobi, Ministry of Health Kenya.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Among 777 virally suppressed adults with human immunodeficiency virus on protease-inhibitor–based second-line antiretroviral regimens randomized 1:1 to switch to dolutegravir or remain on a protease inhibitor, there was no difference in incident hypertension (12% in each arm, P = .868) or change in blood pressure over the 48-week study period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PressureBody WeightCardiovascular DiseasesHeterocyclic Compounds, 3-RingHIV InfectionsHIV Integrase InhibitorsHIV Protease InhibitorsAdultFemaleHumansMaleMiddle AgedDrug SubstitutionHypertensionOxazinesPiperazinesPyridonesRisk FactorsDolutegravir

Stichwörter der Autor:innen

blood pressurecardiovascular disease riskincident hypertensionswitch to DTGweight gain

Substanzen

Heterocyclic Compounds, 3-RingHIV Integrase InhibitorsHIV Protease InhibitorsOxazinesPiperazinesPyridonesDolutegravir

Autor:innen und Institutionen

  • Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya.
  • Department of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, Kenya.
  • Department of Family Practice, University of British Columbia, Vancouver, Canada.
  • Department of Medicine, Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, Kenya.
  • Comprehensive Care Center, Kenyatta National Hospital, Nairobi, Kenya.
  • Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom.

ORCID-Profile: Loice Achieng Ombajo, Jeremy Penner, Joseph Nkuranga, Anton Pozniak

Förderung

  • ViiV Healthcare
  • University of Nairobi
  • Ministry of Health Kenya

Zitieren

APA

Ombajo, L. A., Penner, J., Nkuranga, J., Omodi, V., Otieno, E., Ndinya, F., Wahome, S., & Pozniak, A. (2025). Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial. Clinical Infectious Diseases, 80(4), 889-892. https://doi.org/10.1093/cid/ciae514

Vancouver

Ombajo LA, Penner J, Nkuranga J, Omodi V, Otieno E, Ndinya F, et al. Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial. Clinical Infectious Diseases. 2025;80(4):889-892. doi:10.1093/cid/ciae514

BibTeX
@article{Ombajo2025,
  author = {Ombajo, Loice Achieng and Penner, Jeremy and Nkuranga, Joseph and Omodi, Victor and Otieno, Edwin and Ndinya, Florentius and Wahome, Simon and Pozniak, Anton},
  title = {Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {80},
  number = {4},
  pages = {889--892},
  doi = {10.1093/cid/ciae514}
}
Kostenlos starten →